Biotech

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
What's Going On With Viking Therapeutics Stock On Wednesday?
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
What's Going On With Viking Therapeutics Stock On Wednesday?
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend

Biotech Recent News

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Cognition Therapeutics' CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional decline in trials.
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA reviews RSV drug clesrovimab.
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside.
What's Going On With Larimar Therapeutics Stock On Tuesday?
Larimar Therapeutics reports promising FXN level increases with 25 mg nomlabofusp, advancing towards dose escalation for Friedreich's Ataxia treatment.
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in Crohn's disease.
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
Pfizer projects 2025 revenues of $61-$64 billion, adjusted EPS of $2.80-$3.00, and $24-$26 billion in combined SI&A and R&D expenses while reaffirming its 2024 guidance.
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth.
What's Going On With Moderna Stock On Monday?
Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
Larimar Therapeutics shares long-term OLE study data on nomlabofusp, showing increased FXN levels in Friedreich's Ataxia patients and well-tolerated treatment.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved